지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 저널정보
- 대한병리학회 Journal of Pathology and Translational Medicine Journal of Pathology and Translational Medicine 제53권 제4호
- 발행연도
- 2019.1
- 수록면
- 199 - 206 (8page)
이용수
초록· 키워드
오류제보하기
Blockade of the programmed cell death-1 (PD-1) axis has already been established as an effective treatment of non-small cell lung cancer. Immunohistochemistry (IHC) for programmed deathligand 1 (PD-L1) protein is the only available biomarker that can guide treatment with immune checkpoint inhibitors in non-small cell lung cancer. Because each PD-1/PD-L1 blockade was approved together with a specific PD-L1 IHC assay used in the clinical trials, pathologists have been challenged with performing various assays with a limited sample. To provide a more unified understanding of this, several cross-validation studies between platforms have been performed and showed consistent results. However, the interchangeability of assays may be limited in practice because of the risk of misclassification of patients for the treatment. Furthermore, several issues, including the temporal and spatial heterogeneity of PD-L1 expression in the tumor, and the potential for cytology specimens to be used as an alternative to tissue samples for PD-L1 testing, have still not been resolved. In the future, one of the main aims of immunotherapy research should be to find a novel predictive biomarker for PD-1 blockade therapy and a way to combine it with PDL1 IHC and other tests.
목차
등록된 정보가 없습니다.
참고문헌 (57)
참고문헌 신청
Borghaei H / 2015 / Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer / N Engl J Med 373:1627~1639
Brahmer J / 2015 / Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer / N Engl J Med 373:123~135
Reck M / 2016 / Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer / N Engl J Med 375:1823~1833
Herbst RS / 2016 / Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer(KEYNOTE-010) : a randomised controlled trial / Lancet 387:1540~1550
Fehrenbacher L / 2016 / Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer(POPLAR) : a multicentre, open-label, phase 2 randomised controlled trial / Lancet 387:1837~1846
Brahmer J / 2015 / Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer / N Engl J Med 373:123~135
Reck M / 2016 / Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer / N Engl J Med 375:1823~1833
Herbst RS / 2016 / Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer(KEYNOTE-010) : a randomised controlled trial / Lancet 387:1540~1550
Fehrenbacher L / 2016 / Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer(POPLAR) : a multicentre, open-label, phase 2 randomised controlled trial / Lancet 387:1837~1846
함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Peripheral Blood Immune Cell-based Biomarkers in Anti-PD-1/PD-L1 Therapy
Immune Network
2020 .02
-
Overexpression of PD-L1 and PD-L2 Is Associated with Poor Prognosis in Patients with Hepatocellular Carcinoma
Cancer Research and Treatment
2017 .01
-
Metformin Suppresses Both PD-L1 Expression in Cancer Cells and Cancer-Induced PD-1 Expression in Immune Cells to Promote Antitumor Immunity
Annals of Laboratory Medicine
2024 .09
-
Enhanced Anti-tumor Reactivity of Cytotoxic T Lymphocytes Expressing PD-1 Decoy
Immune Network
2016 .04
-
PD-1: A Negative Regulator of Phagocytosis by Tumour-Associated Macrophages in Colon Cancer
JOURNAL OF BACTERIOLOGY AND VIROLOGY
2019 .12
-
PD-L1 Expression and Combined Status of PD-L1/PD-1–Positive Tumor Infiltrating Mononuclear Cell Density Predict Prognosis in Glioblastoma Patients
Journal of Pathology and Translational Medicine
2017 .01
-
Advantages of robotic PD over laparoscopic PD
Annals of Hepato-Biliary-Pancreatic Surgery
2022 .12
-
Baseline Serum Interleukin-6 Levels Predict the Response of Patients with Advanced Non-small Cell Lung Cancer to PD-1/PD-L1 Inhibitors
Immune Network
2020 .06
-
Interpretation of PD-L1 expression in gastric cancer: summary of a consensus meeting of Korean gastrointestinal pathologists
Journal of Pathology and Translational Medicine
2024 .05
-
Interobserver Reproducibility of PD-L1 Biomarker in Non-small Cell Lung Cancer: A Multi-Institutional Study by 27 Pathologists
Journal of Pathology and Translational Medicine
2019 .01
-
Dysphagia Requiring Medical Attention in Parkinson’s Disease: A Korean Population-Based Study
Journal of Korean Medical Science
2023 .04
-
Programmed cell death-ligand 1 assessment in urothelial carcinoma: prospect and limitation
Journal of Pathology and Translational Medicine
2021 .01
-
A Radiosensitivity Gene Signature and PD-L1 Status Predict Clinical Outcome of Patients with Glioblastoma Multiforme in The Cancer Genome Atlas Dataset
Cancer Research and Treatment
2020 .01
-
Drug-loaded microbubble delivery system to enhance PD-L1 blockade immunotherapy with remodeling immune microenvironment
생체재료학회지
2023 .03
-
Association between PD-L1 and HPV Status and the Prognostic Value of PD-L1 in Oropharyngeal Squamous Cell Carcinoma
Cancer Research and Treatment
2016 .01
-
Development of genetically humanized PD-1 mice capable of evaluating preclinical studies of PD-1 immuno-oncology agents
한국실험동물학회 학술발표대회 논문집
2020 .07
-
Immune Checkpoint Programmed Cell Death Protein-1 (PD-1) Expression on Bone Marrow T Cell Subsets in Patients With Plasma Cell Myeloma
Annals of Laboratory Medicine
2021 .01
-
Programmed death-1 (PD-1) expression in cervical intraepithelial neoplasia and its relationship with recurrence after conization
Journal of Gynecologic Oncology
2018 .01
-
PD-L1 Targeted Immunoliposomes with PD-L1 siRNA and HDAC Inhibitor for Anti-Lung Cancer Immunotherapy
대한의생명과학회지
2022 .12
-
Retrospective Molecular Epidemiology Study of PD-L1 Expression in Patients with EGFR-Mutant Non-small Cell Lung Cancer
Cancer Research and Treatment
2018 .01
이 논문의 저자 정보
최근 본 자료
댓글(0)
0